![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Costabel U, Hunninghake GW. ATS/ERS/WASOG state-ment on sarcoidosis. Eur Respir J1999; 14: 735-7.
- Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol 2004; 97: 173–82.
- Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 1977; 63: 86–108.
- Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M. Prognostic determinants of long-term survival in Japanese patients with cardiac sar-coidosis treated with prednisone. Am J Cardiol 2001; 88: 1006–10.
- Le Guludec D, Menad F, Faraggi M, Weinmann P, Bat-testi JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99 m sestamibi tomoscintigraphy. Chest 1994; 106: 1675–82.
- Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP, Crijns HJ. The addi-tional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pul-monary sarcoidosis. Chest 2005; 128: 1629–37.
- Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoido-sis: evaluation of endomyocardial biopsies. Am Heart J1999; 138: 299-302.
- Kiuchi S, Teraoka K, Koizumi K, Takazawa K, Yamashina A. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagno-sis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging 2007; 23: 237–41.
- Takada K, ma Y, Yamamoto M, Satoh T, Morishita M. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 1994; 11: 113–7.
- Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimula-tion in predicting future arrhythmic events in patients with cardiac sarcoidois. Am J Cardiol 2005; 96: 276–82.
- Mezaki T, Chinushi M, Washizuka T, Furushima H, Chi-nushi Y, Ebe K, Okumura H, Aizawa Y. Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis. Requirement of defibrillator implan-tation for the inactive stage of cardiac sarcoidosis. Intern Med 2001; 40: 731–5.
![A worldwide pioneer in biotechnology.]({"type":"image" , "src" : "/sda/112403/JournalAd-Amgen-MPU.png"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})